Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The activity of direct oral anticoagulants (DOAC) is important in acute clinical situations. Recent studies have suggested a strong influence of DOAC on the diluted Russel's Viper Venom Time (dRVVT). Therefore, it may be a suitable screening parameter for antithrombotic plasma activity of different DOAC. This prospective study aims to evaluate the sensitivity and specificity of dRVVT to detect residual DOAC activity at recommended plasma level thresholds.
Methods: A total of 80 patients were recruited, with 20 each treated with one of the four approved DOAC (apixaban, edoxaban, rivaroxaban or dabigatran), respectively. Blood plasma was collected before (baseline), at plasma peak time, and 6 and 12 h after DOAC. DRVVT was measured using the screen (LA1) and confirm (LA2) assay for lupus anticoagulant and compared with DOAC plasma levels. A reference range was calculated based on the dRVVT values of 61 healthy blood donors.
Results: All DOAC significantly prolonged the dRVVT especially at higher DOAC plasma levels. The LA1 time ≥41 s had a sensitivity ≥98% to detect edoxaban, dabigatran and rivaroxaban plasma levels ≥30 ng/mL but it was only 87% for apixaban. Sensitivity was ≥98% for all DOAC with the LA2 assay ≥36 s. The negative predictive value of a DOAC plasma level <30 ng/mL and dRVVT LA2 <36 s was 99%.
Conclusions: The dRVVT confirm assay (LA2) reliably detects residual DOAC plasma levels ≥30 ng/mL and could be useful to rapidly rule out relevant DOAC activity in emergency situations and to guide treatment decisions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijlh.14300 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments.
Drug Des Devel Ther
September 2025
Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, 050051, People's Republic of China.
Background: Apixaban and rivaroxaban are oral direct factor Xa inhibitors, primarily eliminated through CYP3A4-mediated metabolism and direct intestinal excretion. Previous studies suggest that palbociclib, a CDK4/6 inhibitor, may increase the systemic exposure of these anticoagulants; however, the specific pharmacokinetic mechanisms remain unclear. This study aims to evaluate the effects of palbociclib on the pharmacokinetics of apixaban and rivaroxaban using a rat model to optimize combined drug regimens.
View Article and Find Full Text PDFFibrinography and thrombography (thrombodynamics-4D) in atrial fibrillation assessment of direct oral anticoagulants in geriatrics patients aged 80 years and older receiving direct oral anticoagulant therapy.
Res Pract Thromb Haemost
July 2025
INSERM UMR_S1140, Université Paris Cité, Paris, France.
Background: Scarce data are available on pharmacodynamic (PD) variability in very elderly patients receiving direct oral anticoagulants (DOACs) for atrial fibrillation (AF). Thrombodynamics-4D (TD-4D), which simultaneously assesses fibrin clot formation and thrombin generation, has not yet been tested in patients on rivaroxaban, apixaban, or dabigatran.
Objectives: To (i) evaluate TD-4D's ability to assess DOAC effect added to normal plasma; (ii) assess DOAC PD in very elderly patients with AF along with DOAC concentrations; (iii) identify factors associated with interindividual variability of DOAC PD at peak and trough levels.
Structural equation modelling of nucleotide polymorphisms and pharmacokinetics in direct oral anticoagulant use for stroke and embolism prevention in atrial fibrillation.
Eur J Pharmacol
August 2025
Department of Pharmacy, College of Pharmacy, China Medical University, Taichung, 406040, Taiwan; Department of Pharmacy, China Medical University Hospital, Taichung, 404332, Taiwan; College of Healthcare Administration, Asia University, Taichung, 413542, Taiwan. Electronic address:
Background: Genetic factors affect DOAC pharmacokinetics and efficacy in atrial fibrillation (AF) patients, yet no pharmacogenomic guidelines exist. This study aims to assess their impact on supporting personalized therapy.
Methods: Following PRISMA-2020 (PROSPERO: CRD42024592412), a systematic review analysed 31 studies with 8558 AF patients across Asia and Europe.
Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use.
Stroke
July 2025
Department of Neurology, Stroke Research Center Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland. (T.R.M., P.B., F.Z.-M., U.F., D.J.S.).
Background: Intravenous thrombolysis (IVT) in patients with recent ingestion of direct oral anticoagulants (DOACs) is a frequent challenge and remains controversial. The benefit of DOAC reversal before IVT is uncertain.
Methods: Using target trial methodology, we analyzed data from 28 comprehensive stroke centers.
Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events.
J Thromb Haemost
July 2025
Coagulation Service & Thrombosis Research Unit, Scientific Institute San Raffaele, Milano, Italy.
Background: Direct oral anticoagulants (DOACs) are standard therapy to prevent thromboembolic events in nonvalvular atrial fibrillation (NVAF) and are generally used without routine monitoring of plasma anti-Xa or anti-IIa levels.
Objectives: This study aimed to assess whether plasma levels of anti-Xa or anti-IIa at the time of presentation are associated with acute thromboembolic or bleeding events in DOAC-treated patients with NVAF.
Methods: This prospective case-control study included consecutive long-term DOAC-treated patients with NVAF presenting to a European emergency department with acute thromboembolic or bleeding events (cases), or for other medical reasons (controls).